Developing breakthrough AXL therapeutics to improve patients' lives

Learn About Us

Rights issue 2023

Old woman

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases including cancer and severe respiratory infections

Recent News

BerGenBio Announces Data from Bemcentinib Trial in Mesothelioma Presented at ASCO

BerGenBio to Participate in Investor Webcast and Q&A

BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

BerGenBio ASA - Commencement of the subscription period for the rights issue

BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue

BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

BGBIO – Ex. subscription rights today

BerGenBio ASA: Annual general meeting held

BerGenBio ASA – Updated key information relating to the preferential rights issue

All news